Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

← catalyst calendar

NCT03762850 · results posted

Sponsored by Travere Therapeutics, Inc. (industry) · TVTX — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
406actual
Sites
162
Countries
Australia, Belgium, Croatia +15

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-12-11actualWhen the study began enrolling
Primary completion2023-08-07actualThe date the last participant is measured for the primary outcome — the readout window
Study completionJul 2026estimatedThe whole study's end, after follow-up
First posted2018-12-04actualWhen this record first appeared on the registry
Results posted2024-07-03actualWhen the sponsor posted results to the registry
Record updated2026-04-20actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Immunoglobulin A Nephropathy

Interventions

  • Drug: sparsentan — also filed as RE-021
  • Drug: irbesartan — also filed as Irbesartan Tablets USP
  • Drug: Dapagliflozin

Primary outcome

what the primary-completion date above is the date OF
Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36
measured Baseline (Day 1) and at Week 36

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2022-11-22 · 2.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-07-21 · 853 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · TVTX's whole pipeline · Catalyst calendar · Every registered study · What changed